ArticleNature communications2026
General access to azoles through tailored nitrogen-nitrogen bond construction.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cyclic compounds containing a nitrogen-nitrogen bond are highly significant in chemistry and pharmacology due to their unique structures and versatile chemical properties. The diverse range of available cyclic nitrogen-nitrogen containing compounds offers numerous applications due to their stability, reactivity, and biological activity, making them attractive targets for diverse applications, from materials science to medicinal chemistry. In materials science, their optical and electronic properties make them useful in dyes, pigments, and photoresponsive materials and in medicinal chemistry they provide a foundational scaffold for creating drugs with specific biological functions, particularly in targeting nucleic acids, enzymes, and receptors. However, technologies that enable direct construction of the key nitrogen-nitrogen bond are elusive. Here, this limitation is addressed by disclosing a tailored copper-mediated technology that enables direct nitrogen-nitrogen bond formation from prevalent reagents. The developed process is believed to proceed through a decarboxylative skeletal editing pathway involving both carbon-nitrogen bond cleavage and nitrogen-nitrogen bond construction, offering a modular approach for straightforward access to a wide set of decorated nitrogen-containing heterocyclic scaffolds for widespread adoption.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.